BioMedNewsBreaks — ARMR Sciences Inc. Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.

ARMR Sciences completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent, as the company advances toward human trials for its fentanyl vaccine. Backed by the U.S. Department of War, the vaccine is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression.

To view the announcement, visit https://ibn.fm/t39w2

About ARMR Sciences Inc.

ARMR Sciences Inc. is America’s biodefense technology company, developing next-generation countermeasures against synthetic drug threats, such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the U.S. Department of Defense. ARMR is pioneering the first long-acting, preventive immunotherapy to stop synthetic drug overdose before it begins, starting with fentanyl, the #1 killer of U.S. adults aged 18 to 45. This represents a critical shift in national strategy: from reacting to overdoses to preventing them at the source. Qualified prospective investors who meet the qualifications of an “accredited investor”* can invest $5,000 in this offering and become a shareholder and owner of ARMR.

For more information, visit https://armrsciences.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN